Sanifit closed a 3.6 million euros financing round

Sanifit has accomplished a series B capital increase of 3.6 million Euros in an operation led by “la Caixa”. The venture capital firm HealthEquity, the company Somtobir, and the Nefrona Foundation were also involved in this round. The entrance of a group of private investors with extensive experience in the field of life sciences, among which are several ex – Phadia managers, is also worth mentioning. It is the largest financing round of 2014 in the biotechnology sector in Spain.

Laboratoris Sanifit is dedicated to the development of therapeutic solutions for the treatment of diseases related to calcium. Specifically, SNF472 is an experimental drug for the treatment of cardiovascular disease in haemodialysis patients. This product has already completed all Phase 1 studies in healthy volunteers and is about to start trials in patients.

This capital will allow Sanifit to take the project to the next phase of development, a phase 1b / 2a clinical trial to be run at the Hospital Clinic of Barcelona with dialysis patients.

 

Related articles

Ibereconomía – La Caixa premia la biotecnología made in Baleares

Ascri (Cinco días) – Sanifit logra 3,6 millones de financiación